德琪医药塞利尼索15项研究及成果将在2021 ASCO公布

致力于研发和商业化创新肿瘤疗法的领先生物制药公司——德琪医药有限公司（简称“德琪医药”）今日宣布，同类首款选择性核输出抑制剂——塞利尼索（selinexor）15项研究及成果将在2021年美国临床肿瘤学大会（ASCO）年会上公布。此届ASCO会议于6月4日至6月8日在线上召开。

线上摘要

Effectsofweeklyselinexor,bortezomib,dexamethasone(XVd)versusstandardtwiceweeklybortezomibanddexamethasone(Vd)onRAS-mutatedpreviouslytreatedmultiplemyeloma (MM).

摘要编号：8027

Effectsofrefractorystatustolenalidomideonsafetyandefficacyofselinexor,bortezomib,anddexamethasone(XVd)versusbortezomibanddexamethasone(Vd)inpatientswithpreviouslytreatedmultiplemyeloma.

摘要编号：8024

Survivalamongolderpatientswithpreviouslytreatedmultiplemyeloma treatedwithselinexor,bortezomib,anddexamethasone(XVd)intheBOSTONstudy.

摘要编号：8019

Updatedoverallsurvivalofeltanexorforthetreatmentofpatientswithhypomethylatingagentrefractorymyelodysplasticsyndrome.

摘要编号：e19037

Resultsofthephase2MARCHStudy:OralATG-010(Selinexor)pluslowdosedexamethasoneinChinesepatientswithrelapsed/refractorymultiplemyeloma (RRMM)previouslytreatedwithanimmunomodulatoryagent(IMiD)anda proteasomeinhibitor(PI).

摘要编号：e20002

Oralselinexor,pomalidomide,anddexamethasone(XPd)atrecommendedphase2doseinrelapsedrefractorymultiplemyeloma (MM).

摘要编号：8018

SIENDO/ENGOT-EN5/GOG-3055:Arandomizedphase3trialofmaintenanceselinexorversusplaceboaftercombinationplatinum-basedchemotherapyinadvancedorrecurrentendometrialcancer.

摘要编号：TPS5610

Open-labelphase1studyevaluatingthetolerabilityandanti-tumoractivityofselinexorandpembrolizumabincolorectalcancer.

摘要编号：e15579

Aphase1/2studyofselinexorincombinationwithstandardofcaretherapyfornewlydiagnosedorrecurrentglioblastoma.

摘要编号：TPS2071

AphaseIb/IIstudyofselinexorincombinationwithimatinibinpatientswithadvancedgastrointestinalstromaltumor(GIST):SeliGIST/GEIS-41trial.

摘要编号：11534

Selinexorincombinationwithweeklypaclitaxelinpatientswithadvancedormetastaticsolidtumors:Resultsofanopenlabel,single-center,multiarmphase1bstudy.

摘要编号：5565

Onceweeklyselinexor,carfilzomib,anddexamethasone(XKd)incarfilzomibnonrefractorymultiplemyeloma (MM)patients.

摘要编号：8038

Arandomized,open-label,phase3studyoflow-doseselinexorandlenalidomide(Len)versuslenmaintenancepostautologousstemcelltransplant(ASCT)fornewlydiagnosedmultiplemyeloma (NDMM):ALLGMM23,Sealand.

摘要编号：TPS8055

Molecularpredictorsofresponsetoselinexorinadvancedunresectablede-differentiatedliposarcoma (DDLS).

摘要编号：11509

Selinexorcontainingregimensinpatientswithmultiplemyeloma (MM)previouslytreatedwithanti-CD38monoclonalantibodies(αCD38mAbs).

摘要编号：e20020

关于德琪医药

德琪医药有限公司（简称“德琪医药”）是一家以研发为驱动的生物制药领先企业，致力于为亚太乃至全球患者提供最领先的疗法，治疗肿瘤及其他危及生命的疾病。自2017年正式运营以来，德琪医药通过合作引进和自主研发，建立了一条从临床前到临床阶段不断延展的丰富产品管线。目前，德琪医药已在多个亚太市场获得15个临床批件（IND），并递交了5个新药上市申请（NDA）。德琪医药将以“医者无疆，创新永续”为愿景，专注于同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，解决亟待满足的临床需求。